BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy

NCT01672671 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Early Triple Negative Breast Cancer

Interventions

DRUG: Doxorubicin, Paclitaxel, Cisplatin

Sponsor

Russian Academy of Medical Sciences